Paulina Hill

Paulina was on the healthcare team at Polaris Partners since 2012, and is now a Biotech investor at Omega Funds. Paulina is currently an observer on the board of Arrakis Therapeutics. Paulina previously served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Lyra Pharmaceuticals, Faraday Pharmaceuticals, Arsenal Medical and CAMP4 Therapeutics, where she was the founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at the Massachusetts Institute of Technology. Paulina was the founding president of the MIT Postdoctoral Association and served on the MIT Intellectual Property Presidential Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry.